{
  "thread": {
    "uuid": "25369ab1fdc500861b729bcd9896b20e2024320f",
    "url": "https://www.bioworld.com/articles/723258-lowering-the-mast-eoe-theory-down-after-celldex-phase-ii?v=preview",
    "site_full": "www.bioworld.com",
    "site": "bioworld.com",
    "site_section": "https://bioworld.com/topics/84-bioworld",
    "site_categories": [
      "media"
    ],
    "section_title": "BioWorld: The Daily Biopharmaceutical News Source",
    "site_title": "BioWorld: The Daily Biopharmaceutical and Medical Technology News Source",
    "title": "Lowering the mast: EoE theory down after Celldex phase II | BioWorld",
    "title_full": "Lowering the mast: EoE theory down after Celldex phase II | BioWorld",
    "published": "2025-08-20T08:00:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "IN",
    "main_image": "https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/mast-cell-histamine-illustration.jpg?height=635&amp;t=1755723604&amp;width=1200",
    "performance_score": 0,
    "domain_rank": 54203,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "25369ab1fdc500861b729bcd9896b20e2024320f",
  "url": "https://www.bioworld.com/articles/723258-lowering-the-mast-eoe-theory-down-after-celldex-phase-ii?v=preview",
  "ord_in_thread": 0,
  "author": "Randy Osborne",
  "published": "2025-08-20T08:00:00.000+03:00",
  "title": "Lowering the mast: EoE theory down after Celldex phase II | BioWorld",
  "text": "Celldex Therapeutics Inc. will not advance barzolvolimab (CDX-0159, barzo) in eosinophilic esophagitis (EoE) after taking a look at top-line data from the ongoing phase II effort. The study met its primary endpoint, proving barzo’s efficacy in depleting mast cells in the gastrointestinal (GI) tract, but this didn’t improve symptoms of EoE – a chronic inflammatory disease of the esophagus – which means mast cells are not a primary driver. Hampton, N.J.-based Celldex noted that barzo did turn up a favorable safety profile.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "negative",
  "categories": [
    "Economy, Business and Finance",
    "Science and Technology",
    "Social Issue"
  ],
  "topics": [
    "Economy, Business and Finance->business reporting and performance",
    "Economy, Business and Finance->healthcare industry",
    "Science and Technology->biotechnology",
    "Science and Technology->biomedical science",
    "Science and Technology->medical research",
    "Social Issue->social problem",
    "Social Issue->social services",
    "Social Issue->population and census"
  ],
  "ai_allow": true,
  "has_canonical": true,
  "breaking": null,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": [
      {
        "name": "Celldex Therapeutics Inc.",
        "sentiment": "negative",
        "tickers": []
      }
    ]
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-08-21T10:31:50.983+03:00",
  "updated": "2025-08-21T10:36:29.000+03:00"
}